Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks to the ...

(Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in revenue by the early 2030s, thanks ...

Discover how rising healthcare spending can be turned into income growth. Build a retirement portfolio that thrives in a key ...

Trump’s possible next move, Winklevoss twins jump into hot IPO market, Palo Alto Networks issues rosy guidance, and more news ...

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

The string of negative updates from Novo Nordisk and positive news flow from the main competitor Eli Lilly has finally ended ...

Dining under palm trees on a patio at Mar-a-Lago in December, President-elect Donald Trump reassured chief executives at ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk stock rallies as the Danish pharma giant makes two big announcements. TD Cowen analysts recommend buying NVO ...

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Discover how weight-loss drugs like Wegovy and Mounjaro are being tested for a range of health conditions including alcohol addiction, Alzheimer's disease, and cardiovascular issues. Learn about their ...